{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:59:08Z","timestamp":1793152748195,"version":"4.5.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T00:00:00Z","timestamp":1771545600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,3,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Retinoic acid signaling, mediated through its receptors (RARs and RXRs), plays a fundamental role in regulating cell differentiation, proliferation, and apoptosis. While well established in hematologic malignancies, particularly acute promyelocytic leukemia, its therapeutic potential in breast cancer remains underexplored. Emerging evidence has identified aberrant epigenetic regulation of retinoic acid receptors as a central mechanism of resistance to retinoic acid. This review integrates recent advances in epigenetic control, receptor biology, and translational studies to re-evaluate the therapeutic potential of retinoic acid in breast cancer. Among the many factors that influence retinoic acid signaling are reduced receptor expression and altered intracellular delivery of retinoic acid. Promoter hypermethylation and histone deacetylation silence\n                    <jats:italic>RAR\u03b22<\/jats:italic>\n                    and disrupt canonical retinoic acid transcriptional networks, while imbalanced intracellular routing via CRABP2 and FABP5 and subtype-specific expression of RAR isoforms further determine therapeutic outcomes. Luminal tumors with preserved RAR\u03b1 and CRABP2 expression display strong retinoic acid sensitivity, in contrast to HER2-enriched and triple-negative subtypes, where\n                    <jats:italic>MYC<\/jats:italic>\n                    -driven\n                    <jats:italic>CRABP2<\/jats:italic>\n                    suppression and DNA hypermethylation confer retinoid resistance. Epigenetic therapies using DNMT or HDAC inhibitors can restore RAR\u03b22 expression and resensitize tumors. Combination regimens such as retinoic acid with entinostat and doxorubicin achieve potent antitumor synergy in preclinical models. Retinoic acid also remodels the tumor microenvironment by modulating angiogenesis, fibroblast activation, and immune responses, although stromal RAR\u03b2 signaling can paradoxically promote tumor progression. Early clinical trials lacked biomarker stratification and were limited by unfavorable pharmacokinetics, likely obscuring therapeutic benefit. Future clinical development should focus on biomarker-driven patient stratification, pharmacological optimization, and rational combination strategies that integrate retinoids with targeted or immune-based therapies. Notably, emerging methylation-based classifiers that identify retinoid-responsive triple-negative breast cancer subsets, together with the paradoxical pro-tumorigenic effects of stromal RAR\u03b2, underscore the novelty and translational significance of integrating tumor-intrinsic and microenvironmental determinants of retinoid sensitivity. Together, these approaches may help re-establish functional retinoid signaling and realize the therapeutic potential of retinoic acid in breast cancer.\n                  <\/jats:p>","DOI":"10.1038\/s41388-026-03699-8","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T07:38:42Z","timestamp":1771573122000},"page":"961-970","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Association of retinoids, retinoic acid receptors and epigenetics in breast cancer"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0148-541X","authenticated-orcid":false,"given":"\u0141ukasz","family":"Szyma\u0144ski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3430-5876","authenticated-orcid":false,"given":"Tino","family":"Schenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"\u0141awi\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annamaria","family":"Brioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7968-9888","authenticated-orcid":false,"given":"Arthur","family":"Zelent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,20]]},"reference":[{"key":"3699_CR1","first-page":"477","volume":"74","author":"AN Giaquinto","year":"2024","unstructured":"Giaquinto AN, Sung H, Newman LA, Freedman RA, Smith RA, Star J, et al. Breast cancer statistics 2024. CA Cancer J Clin. 2024;74:477\u201395.","journal-title":"CA Cancer J Clin"},{"key":"3699_CR2","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.2217\/14622416.9.12.1879","volume":"9","author":"P-K Lo","year":"2008","unstructured":"Lo P-K, Sukumar S. Epigenomics and breast cancer. Pharmacogenomics. 2008;9:1879\u2013902.","journal-title":"Pharmacogenomics"},{"key":"3699_CR3","doi-asserted-by":"publisher","first-page":"1556","DOI":"10.1038\/sj.onc.1203456","volume":"19","author":"SM Sirchia","year":"2000","unstructured":"Sirchia SM, Ferguson AT, Sironi E, Subramanyan S, Orlandi R, Sukumar S, et al. Evidence of epigenetic changes affecting the chromatin state of the retinoic acid receptor beta2 promoter in breast cancer cells. Oncogene. 2000;19:1556\u201363.","journal-title":"Oncogene"},{"key":"3699_CR4","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1016\/j.cell.2009.04.043","volume":"137","author":"S Hua","year":"2009","unstructured":"Hua S, Kittler R, White KPA. Genomic mechanism for antagonism between retinoic acid and estrogen signaling in breast cancer. Cell. 2009;137:1259\u201371.","journal-title":"Cell"},{"key":"3699_CR5","doi-asserted-by":"publisher","first-page":"950","DOI":"10.15252\/emmm.201404670","volume":"7","author":"F Centritto","year":"2015","unstructured":"Centritto F, Paroni G, Bolis M, Garattini SK, Kurosaki M, Barzago MM, et al. Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: luminal phenotype and RAR\u03b1 expression. EMBO Mol Med. 2015;7:950\u201372.","journal-title":"EMBO Mol Med"},{"key":"3699_CR6","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.3390\/jcm9113490","volume":"9","author":"L Costantini","year":"2020","unstructured":"Costantini L, Merendino N. Polyunsaturated fatty acids and microbiota relationship: implications in cancer onset and treatment. J Clin Med. 2020;9:3490.","journal-title":"J Clin Med"},{"key":"3699_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01492-2","volume":"22","author":"MA Caricasulo","year":"2024","unstructured":"Caricasulo MA, Zanetti A, Terao M, Garattini E, Paroni G. Cellular and micro-environmental responses influencing the antitumor activity of all-trans retinoic acid in breast cancer. Cell Commun Signal. 2024;22:127.","journal-title":"Cell Commun Signal"},{"key":"3699_CR8","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/35106036","volume":"1","author":"L Altucci","year":"2001","unstructured":"Altucci L, Gronemeyer H. The promise of retinoids to fight against cancer. Nat Rev Cancer. 2001;1:181\u201393.","journal-title":"Nat Rev Cancer"},{"key":"3699_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1101\/gad.14.2.121","volume":"14","author":"CK Glass","year":"2000","unstructured":"Glass CK, Rosenfeld MG. The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev. 2000;14:121\u201341.","journal-title":"Genes Dev"},{"key":"3699_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-12-3175","volume":"19","author":"RM Connolly","year":"2013","unstructured":"Connolly RM, Nguyen NK, Sukumar S. Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment. Clin Cancer Res. 2013;19:1651\u201359.","journal-title":"Clin Cancer Res"},{"key":"3699_CR11","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1300874","volume":"369","author":"F Lo-Coco","year":"2013","unstructured":"Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013;369:111\u201321.","journal-title":"N Engl J Med"},{"key":"3699_CR12","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.ctrv.2014.01.001","volume":"40","author":"E Garattini","year":"2014","unstructured":"Garattini E, Bolis M, Garattini SK, Fratelli M, Centritto F, Paroni G, et al. Retinoids and breast cancer: from basic studies to the clinic and back again. Cancer Treat Rev. 2014;40:739\u201349.","journal-title":"Cancer Treat Rev"},{"key":"3699_CR13","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/cancers10110397","volume":"10","author":"KM Coyle","year":"2018","unstructured":"Coyle KM, Dean CA, Thomas ML, Vidovic D, Giacomantonio CA, Helyer L, et al. DNA methylation predicts the response of triple-negative breast cancers to all-trans retinoic acid. Cancers. 2018;10:397.","journal-title":"Cancers"},{"key":"3699_CR14","doi-asserted-by":"publisher","first-page":"3521","DOI":"10.1111\/febs.17151","volume":"291","author":"W-S Choi","year":"2024","unstructured":"Choi W-S, Liu R-Z, Mak C, Maadi H, Godbout R. Overcoming retinoic acid resistance in HER2-enriched breast cancers: role of MYC. FEBS J. 2024;291:3521\u201338.","journal-title":"FEBS J"},{"key":"3699_CR15","doi-asserted-by":"publisher","first-page":"543","DOI":"10.3390\/biomedicines9050543","volume":"9","author":"G Augimeri","year":"2021","unstructured":"Augimeri G, Bonofiglio D. PPARgamma: a potential intrinsic and extrinsic molecular target for breast cancer therapy. Biomedicines. 2021;9:543.","journal-title":"Biomedicines"},{"key":"3699_CR16","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.3390\/cancers12092623","volume":"12","author":"G Augimeri","year":"2020","unstructured":"Augimeri G, Giordano C, Gelsomino L, Plastina P, Barone I, Catalano S, et al. The role of ppar\u03b3 ligands in breast cancer: from basic research to clinical studies. Cancers. 2020;12:2623.","journal-title":"Cancers"},{"key":"3699_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07559-w","volume":"20","author":"H Xu","year":"2020","unstructured":"Xu H, Liu Z, Shi H, Wang C. Prognostic role of vitamin D receptor in breast cancer: a systematic review and meta-analysis. BMC Cancer. 2020;20:1051.","journal-title":"BMC Cancer"},{"key":"3699_CR18","doi-asserted-by":"publisher","first-page":"R33","DOI":"10.1530\/ERC-21-0182","volume":"29","author":"J Vanhevel","year":"2022","unstructured":"Vanhevel J, Verlinden L, Doms S, Wildiers H, Verstuyf A. The role of vitamin D in breast cancer risk and progression. Endocr Relat Cancer. 2022;29:R33\u2013R55.","journal-title":"Endocr Relat Cancer"},{"key":"3699_CR19","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.tem.2009.11.004","volume":"21","author":"Y-Y Liu","year":"2010","unstructured":"Liu Y-Y, Brent GA. Thyroid hormone crosstalk with nuclear receptor signaling in metabolic regulation. Trends Endocrinol Metab. 2010;21:166\u201373.","journal-title":"Trends Endocrinol Metab"},{"key":"3699_CR20","doi-asserted-by":"publisher","first-page":"957","DOI":"10.3390\/ijms22020957","volume":"22","author":"AZ Zehni","year":"2021","unstructured":"Zehni AZ, Batz F, Vattai A, Kaltofen T, Schrader S, Jacob S-N, et al. The prognostic impact of retinoid X receptor and thyroid hormone receptor alpha in unifocal vs. multifocal\/multicentric breast cancer. Int J Mol Sci. 2021;22:957.","journal-title":"Int J Mol Sci"},{"key":"3699_CR21","doi-asserted-by":"publisher","first-page":"e1009220","DOI":"10.1371\/journal.ppat.1009220","volume":"17","author":"H Feng","year":"2021","unstructured":"Feng H, Zhang Y-B, Gui J-F, Lemon SM, Yamane D. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses. PLoS Pathog. 2021;17:e1009220.","journal-title":"PLoS Pathog"},{"key":"3699_CR22","doi-asserted-by":"publisher","first-page":"41324","DOI":"10.18632\/oncotarget.5847","volume":"6","author":"Y-T Oh","year":"2015","unstructured":"Oh Y-T, Yue P, Wang D, Tong J-S, Chen ZG, Khuri FR, et al. Suppression of death receptor 5 enhances cancer cell invasion and metastasis through activation of caspase-8\/TRAF2-mediated signaling. Oncotarget. 2015;6:41324\u201338.","journal-title":"Oncotarget"},{"key":"3699_CR23","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s10555-018-9728-y","volume":"37","author":"X Yuan","year":"2018","unstructured":"Yuan X, Gajan A, Chu Q, Xiong H, Wu K, Wu GS. Developing TRAIL\/TRAIL death receptor-based cancer therapies. Cancer Metastasis Rev. 2018;37:733\u201348.","journal-title":"Cancer Metastasis Rev"},{"key":"3699_CR24","doi-asserted-by":"publisher","first-page":"12089","DOI":"10.3390\/ijms241512089","volume":"24","author":"G Brown","year":"2023","unstructured":"Brown G. Deregulation of all-trans retinoic acid signaling and development in cancer. Int J Mol Sci. 2023;24:12089.","journal-title":"Int J Mol Sci"},{"key":"3699_CR25","doi-asserted-by":"publisher","first-page":"233","DOI":"10.4048\/jbc.2018.21.e41","volume":"21","author":"DC Temian","year":"2018","unstructured":"Temian DC, Pop LA, Irimie AI, Berindan-Neagoe I. The epigenetics of triple-negative and basal-like breast cancer: current knowledge. J Breast Cancer. 2018;21:233\u201343.","journal-title":"J Breast Cancer"},{"key":"3699_CR26","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.7150\/jca.119306","volume":"16","author":"Y Zhou","year":"2025","unstructured":"Zhou Y, Liu H, Hong W, Su H, Mu Y, Cheng Y, et al. Epigenetic regulation espeically histone modifications in breast cancer: a viable and emerging targeted therapeutic strategy. J Cancer. 2025;16:4037\u201346.","journal-title":"J Cancer"},{"key":"3699_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2022.166552","volume":"1868","author":"Q Babar","year":"2022","unstructured":"Babar Q, Saeed A, Tabish TA, Pricl S, Townley H, Thorat N. Novel epigenetic therapeutic strategies and targets in cancer. Biochim Biophys Acta Mol Basis Dis. 2022;1868:166552.","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"3699_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.708765","volume":"11","author":"K Otmani","year":"2021","unstructured":"Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: mechanism of deregulation and clinical implications. Front Oncol. 2021;11:708765.","journal-title":"Front Oncol"},{"key":"3699_CR29","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1756-8722-6-37","volume":"6","author":"H Zhang","year":"2013","unstructured":"Zhang H, Chen Z, Wang X, Huang Z, He Z, Chen Y. Long non-coding RNA: a new player in cancer. J Hematol Oncol. 2013;6:37.","journal-title":"J Hematol Oncol"},{"key":"3699_CR30","first-page":"1","volume":"11","author":"M Hashemi","year":"2024","unstructured":"Hashemi M, Fard AA, Pakshad B, Asheghabadi PS, Hosseinkhani A, Hosseini AS, et al. Non-coding RNAs and regulation of the PI3K signaling pathway in lung cancer: recent insights and potential clinical applications. Noncoding RNA Res. 2024;11:1\u201321.","journal-title":"Noncoding RNA Res"},{"key":"3699_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2023.104156","volume":"192","author":"N Jan","year":"2023","unstructured":"Jan N, Sofi S, Qayoom H, Haq BU, Shabir A, Mir MA. Targeting breast cancer stem cells through retinoids: a new hope for treatment. Crit Rev Oncol Hematol. 2023;192:104156.","journal-title":"Crit Rev Oncol Hematol"},{"key":"3699_CR32","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.canlet.2006.05.013","volume":"247","author":"Z Zhang","year":"2007","unstructured":"Zhang Z, Joh K, Yatsuki H, Zhao W, Soejima H, Higashimoto K, et al. Retinoic acid receptor beta2 is epigenetically silenced either by DNA methylation or repressive histone modifications at the promoter in cervical cancer cells. Cancer Lett. 2007;247:318\u201327.","journal-title":"Cancer Lett"},{"key":"3699_CR33","first-page":"2455","volume":"62","author":"SM Sirchia","year":"2002","unstructured":"Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res. 2002;62:2455\u201361.","journal-title":"Cancer Res"},{"key":"3699_CR34","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1073\/pnas.1011845108","volume":"108","author":"X Liu","year":"2011","unstructured":"Liu X, Nugoli M, Laferri\u00e8re J, Saleh SM, Rodrigue-Gervais IG, Saleh M, et al. Stromal retinoic acid receptor beta promotes mammary gland tumorigenesis. Proc Natl Acad Sci USA. 2011;108:774\u201379.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3699_CR35","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.3390\/cancers12082275","volume":"12","author":"S Rossetti","year":"2020","unstructured":"Rossetti S, Sacchi N. Emerging cancer epigenetic mechanisms regulated by all-trans retinoic acid. Cancers. 2020;12:2275.","journal-title":"Cancers"},{"key":"3699_CR36","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1158\/0008-5472.CAN-15-1619","volume":"76","author":"VF Merino","year":"2016","unstructured":"Merino VF, Nguyen N, Jin K, Sadik H, Cho S, Korangath P, et al. Combined treatment with epigenetic, differentiating, and chemotherapeutic agents cooperatively targets tumor-initiating cells in triple-negative breast cancer. Cancer Res. 2016;76:2013\u201324.","journal-title":"Cancer Res"},{"key":"3699_CR37","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1158\/1535-7163.MCT-04-0079","volume":"4","author":"NP Mongan","year":"2005","unstructured":"Mongan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2\u2019-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther. 2005;4:477\u201386.","journal-title":"Mol Cancer Ther"},{"key":"3699_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-018-1068-x","volume":"20","author":"VF Merino","year":"2018","unstructured":"Merino VF, Cho S, Nguyen N, Sadik H, Narayan A, Talbot C, et al. Induction of cell cycle arrest and inflammatory genes by combined treatment with epigenetic, differentiating, and chemotherapeutic agents in triple-negative breast cancer. Breast Cancer Res. 2018;20:145.","journal-title":"Breast Cancer Res"},{"key":"3699_CR39","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.cell.2007.02.050","volume":"129","author":"TT Schug","year":"2007","unstructured":"Schug TT, Berry DC, Shaw NS, Travis SN, Noy N. Dual transcriptional activities underlie opposing effects of retinoic acid on cell survival. Cell. 2007;129:723\u201333.","journal-title":"Cell"},{"key":"3699_CR40","doi-asserted-by":"publisher","first-page":"7546","DOI":"10.1073\/pnas.0709981105","volume":"105","author":"TT Schug","year":"2008","unstructured":"Schug TT, Berry DC, Toshkov IA, Cheng L, Nikitin AY, Noy N. Overcoming retinoic acid-resistance of mammary carcinomas by diverting retinoic acid from PPARbeta\/delta to RAR. Proc Natl Acad Sci USA. 2008;105:7546\u201351.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3699_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4966-5","volume":"18","author":"V Dobrotkova","year":"2018","unstructured":"Dobrotkova V, Chlapek P, Mazanek P, Sterba J, Veselska R. Traffic lights for retinoids in oncology: molecular markers of retinoid resistance and sensitivity and their use in the management of cancer differentiation therapy. BMC Cancer. 2018;18:1059.","journal-title":"BMC Cancer"},{"key":"3699_CR42","doi-asserted-by":"publisher","first-page":"360","DOI":"10.3390\/jcm9020360","volume":"9","author":"L Costantini","year":"2020","unstructured":"Costantini L, Molinari R, Farinon B, Merendino N. Retinoic acids in the treatment of most lethal solid cancers. J Clin Med. 2020;9:360.","journal-title":"J Clin Med"},{"key":"3699_CR43","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s12672-025-01783-1","volume":"16","author":"X Xue","year":"2025","unstructured":"Xue X, Li Z, Zhao J, Zhao Z, Li Z, Li Y, et al. Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance. Discov Oncol. 2025;16:61.","journal-title":"Discov Oncol"},{"key":"3699_CR44","doi-asserted-by":"publisher","first-page":"21414","DOI":"10.1074\/jbc.M201885200","volume":"277","author":"F Lin","year":"2002","unstructured":"Lin F, Kolluri SK, Chen G, Zhang X. Regulation of retinoic acid-induced inhibition of AP-1 activity by orphan receptor chicken ovalbumin upstream promoter-transcription factor. J Biol Chem. 2002;277:21414\u201322.","journal-title":"J Biol Chem"},{"key":"3699_CR45","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nm.2661","volume":"18","author":"T Schenk","year":"2012","unstructured":"Schenk T, Chen WC, G\u00f6llner S, Howell L, Jin L, Hebestreit K, et al. Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia. Nat Med. 2012;18:605\u201311.","journal-title":"Nat Med"},{"key":"3699_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16017-x","volume":"11","author":"NK Vinckier","year":"2020","unstructured":"Vinckier NK, Patel NA, Geusz RJ, Wang A, Wang J, Matta I, et al. LSD1-mediated enhancer silencing attenuates retinoic acid signalling during pancreatic endocrine cell development. Nat Commun. 2020;11:2082.","journal-title":"Nat Commun"},{"key":"3699_CR47","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201948597","volume":"21","author":"J Liu","year":"2020","unstructured":"Liu J, Feng J, Li L, Lin L, Ji J, Lin C, et al. Arginine methylation-dependent LSD1 stability promotes invasion and metastasis of breast cancer. EMBO Rep. 2020;21:e48597.","journal-title":"EMBO Rep"},{"key":"3699_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.3892\/ol.2025.14959","volume":"29","author":"L Varisli","year":"2025","unstructured":"Varisli L, Zoumpourlis P, Spandidos DA, Zoumpourlis V, Vlahopoulos S. ALDH1A1 in breast cancer: a prospective target to overcome therapy resistance (Review). Oncol Lett. 2025;29:213.","journal-title":"Oncol Lett"},{"key":"3699_CR49","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/cr.2018.15","volume":"28","author":"Q Wang","year":"2018","unstructured":"Wang Q, Jiang J, Ying G, Xie X-Q, Zhang X, Xu W, et al. Tamoxifen enhances stemness and promotes metastasis of ER\u03b136+ breast cancer by upregulating ALDH1A1 in cancer cells. Cell Res. 2018;28:336\u201358.","journal-title":"Cell Res"},{"key":"3699_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.918778","volume":"12","author":"H Yue","year":"2022","unstructured":"Yue H, Hu Z, Hu R, Guo Z, Zheng Y, Wang Y, et al. ALDH1A1 in cancers: bidirectional function, drug resistance, and regulatory mechanism. Front Oncol. 2022;12:918778.","journal-title":"Front Oncol"},{"key":"3699_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1254612","volume":"11","author":"K Lavudi","year":"2023","unstructured":"Lavudi K, Nuguri SM, Olverson Z, Dhanabalan AK, Patnaik S, Kokkanti RR. Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers. Front Cell Dev Biol. 2023;11:1254612.","journal-title":"Front Cell Dev Biol"},{"key":"3699_CR52","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/348699a0","volume":"348","author":"P Basset","year":"1990","unstructured":"Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P, Limacher JM, et al. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990;348:699\u2013704.","journal-title":"Nature"},{"key":"3699_CR53","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1200\/JCO.2017.35.7_suppl.125","volume":"35","author":"RP Tobin","year":"2017","unstructured":"Tobin RP, Jordan KR, Davis D, McCarter M. Effects of in vitro ATRA treatment on human MDSC expansion and function. J Clin Oncol. 2017;35:125\u201325.","journal-title":"J Clin Oncol"},{"key":"3699_CR54","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1158\/1078-0432.CCR-22-3652","volume":"29","author":"DJ Olson","year":"2023","unstructured":"Olson DJ, Luke JJ. Myeloid maturity: ATRA to enhance Anti-PD-1? Clin Cancer Res. 2023;29:1167\u201369.","journal-title":"Clin Cancer Res"},{"key":"3699_CR55","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.intimp.2018.08.007","volume":"63","author":"RP Tobin","year":"2018","unstructured":"Tobin RP, Jordan KR, Robinson WA, Davis D, Borges VF, Gonzalez R, et al. Targeting myeloid-derived suppressor cells using all-trans retinoic acid in melanoma patients treated with Ipilimumab. Int Immunopharmacol. 2018;63:282\u201391.","journal-title":"Int Immunopharmacol"},{"key":"3699_CR56","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1158\/0008-5472.CAN-17-3415","volume":"78","author":"R Bauer","year":"2018","unstructured":"Bauer R, Udonta F, Wroblewski M, Ben-Batalla I, Santos IM, Taverna F, et al. Blockade of myeloid-derived suppressor cell expansion with all-trans retinoic acid increases the efficacy of antiangiogenic therapy. Cancer Res. 2018;78:3220\u201332.","journal-title":"Cancer Res"},{"key":"3699_CR57","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.aba8426","volume":"6","author":"E Rao","year":"2021","unstructured":"Rao E, Hou Y, Huang X, Wang L, Wang J, Zheng W, et al. All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Sci Immunol. 2021;6:eaba8426.","journal-title":"Sci Immunol"},{"key":"3699_CR58","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2025.113995","volume":"385","author":"H He","year":"2025","unstructured":"He H, Zheng Y, Ji J, Ye C, Sun Y, Peng Y, et al. Liposomal all-trans retinoic acid boosts anti-tumor immunity of radiotherapy via mitigating cancer stemness and remedying tumor microenvironment. J Control Release. 2025;385:113995.","journal-title":"J Control Release"},{"key":"3699_CR59","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1200\/JCO.2001.19.9.2456","volume":"19","author":"M Duvic","year":"2001","unstructured":"Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001;19:2456\u201371.","journal-title":"J Clin Oncol"},{"key":"3699_CR60","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/jnci\/91.21.1847","volume":"91","author":"U Veronesi","year":"1999","unstructured":"Veronesi U, De Palo G, Marubini E, Costa A, Formelli F, Mariani L, et al. Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer. J Natl Cancer Inst. 1999;91:1847\u201356.","journal-title":"J Natl Cancer Inst"},{"key":"3699_CR61","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1158\/1940-6207.CAPR-23-0422","volume":"17","author":"V Aristarco","year":"2024","unstructured":"Aristarco V, Serrano D, Maisonneuve P, Guerrieri-Gonzaga A, Lazzeroni M, Feroce I, et al. Fenretinide in young women at genetic or familial risk of breast cancer: a placebo-controlled biomarker trial. Cancer Prev Res. 2024;17:255\u201363.","journal-title":"Cancer Prev Res"},{"key":"3699_CR62","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.3390\/cancers15143535","volume":"15","author":"Y Nagai","year":"2023","unstructured":"Nagai Y, Ambinder AJ. The promise of retinoids in the treatment of cancer: neither burnt out nor fading away. Cancers. 2023;15:3535.","journal-title":"Cancers"},{"key":"3699_CR63","doi-asserted-by":"publisher","first-page":"87064","DOI":"10.18632\/oncotarget.13500","volume":"7","author":"S Rossetti","year":"2016","unstructured":"Rossetti S, Ren M, Visconti N, Corlazzoli F, Gagliostro V, Somenzi G, et al. Tracing anti-cancer and cancer-promoting actions of all-trans retinoic acid in breast cancer to a RAR\u03b1 epigenetic mechanism of mammary epithelial cell fate. Oncotarget. 2016;7:87064\u201380.","journal-title":"Oncotarget"},{"key":"3699_CR64","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1101\/gad.552910","volume":"24","author":"CS Ross-Innes","year":"2010","unstructured":"Ross-Innes CS, Stark R, Holmes KA, Schmidt D, Spyrou C, Russell R, et al. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 2010;24:171\u201382.","journal-title":"Genes Dev"},{"key":"3699_CR65","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3175","volume":"4","author":"HJ Johansson","year":"2013","unstructured":"Johansson HJ, Sanchez BC, Mundt F, Forshed J, Kovacs A, Panizza E, et al. Retinoic acid receptor alpha is associated with tamoxifen resistance in breast cancer. Nat Commun. 2013;4:2175.","journal-title":"Nat Commun"},{"key":"3699_CR66","doi-asserted-by":"publisher","first-page":"e269","DOI":"10.1097\/SLA.0000000000005004","volume":"274","author":"N Goel","year":"2021","unstructured":"Goel N, Yadegarynia S, Lubarsky M, Choi S, Kelly K, Balise R, et al. Racial and ethnic disparities in breast cancer survival: emergence of a clinically distinct hispanic black population. Ann Surg. 2021;274:e269\u201375.","journal-title":"Ann Surg"},{"key":"3699_CR67","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10549-021-06185-9","volume":"188","author":"PJ Ho","year":"2021","unstructured":"Ho PJ, Dorajoo R, Ivankovi\u0107 I, Ong SS, Khng AJ, Tan BK-T, et al. DNA methylation and breast cancer-associated variants. Breast Cancer Res Treat. 2021;188:713\u201327.","journal-title":"Breast Cancer Res Treat"},{"key":"3699_CR68","doi-asserted-by":"publisher","unstructured":"Founta K, Chambwe N. Genetic ancestry-specific meQTLs control immune function regulation in a breast cancer cohort of African and European patients. 2024, https:\/\/doi.org\/10.1101\/2024.08.29.610316.","DOI":"10.1101\/2024.08.29.610316"},{"key":"3699_CR69","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13046-021-01941-7","volume":"40","author":"S Lou","year":"2021","unstructured":"Lou S, Gao H, Hong H, Zhu Z, Zhao H. Inhibition of retinoic acid receptor \u03b1 phosphorylation represses the progression of triple-negative breast cancer via transactivating miR-3074-5p to target DHRS3. J Exp Clin Cancer Res. 2021;40:141.","journal-title":"J Exp Clin Cancer Res"},{"key":"3699_CR70","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2104162118","volume":"118","author":"W Wu","year":"2021","unstructured":"Wu W, Warner M, Wang L, He W-W, Zhao R, Guan X, et al. Drivers and suppressors of triple-negative breast cancer. Proc Natl Acad Sci USA. 2021;118:e2104162118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3699_CR71","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1158\/2159-8290.CD-17-0399","volume":"7","author":"MR McKeown","year":"2017","unstructured":"McKeown MR, Corces MR, Eaton ML, Fiore C, Lee E, Lopez JT, et al. Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RAR\u03b1 dependency targetable by SY-1425, a potent and selective RAR\u03b1 agonist. Cancer Discov. 2017;7:1136\u201353.","journal-title":"Cancer Discov"},{"key":"3699_CR72","doi-asserted-by":"publisher","unstructured":"Schenk T, Zadegan FG, Fiedler F, Stanko C, \u00d6lsner L, Schuett J, et al. LSD1 and GCN5 inhibition facilitates Am80 (tamibarotene)-mediated differentiation therapy in RARA-high non-APL AML. https:\/\/doi.org\/10.21203\/rs.3.rs-4791108\/v1 2024.","DOI":"10.21203\/rs.3.rs-4791108\/v1"},{"key":"3699_CR73","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1158\/1078-0432.CCR-20-4054","volume":"27","author":"MM Tayari","year":"2021","unstructured":"Tayari MM, Santos HGD, Kwon D, Bradley TJ, Thomassen A, Chen C, et al. Clinical responsiveness to all-trans retinoic acid is potentiated by LSD1 inhibition and associated with a quiescent transcriptome in myeloid malignancies. Clin Cancer Res. 2021;27:1893\u2013903.","journal-title":"Clin Cancer Res"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03699-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03699-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T12:03:06Z","timestamp":1773403386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03699-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,20]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,3,28]]}},"alternative-id":["3699"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03699-8","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,20]]},"assertion":[{"value":"30 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}